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Abstract
Pathological processes involved in the initiation of rheumatoid
synovitis remain unclear. We undertook the present study to
identify immune and stromal processes that are present soon
after the clinical onset of rheumatoid arthritis (RA) by assessing
a panel of T cell, macrophage, and stromal cell related cytokines
and chemokines in the synovial fluid of patients with early
synovitis. Synovial fluid was aspirated from inflamed joints of
patients with inflammatory arthritis of duration 3 months or less,
whose outcomes were subsequently determined by follow up.
For comparison, synovial fluid was aspirated from patients with
acute crystal arthritis, established RA and osteoarthritis.
Rheumatoid factor activity was blocked in the synovial fluid
samples, and a panel of 23 cytokines and chemokines
measured using a multiplex based system. Patients with early
inflammatory arthritis who subsequently developed RA had a
distinct but transient synovial fluid cytokine profile. The levels of
a range of T cell, macrophage and stromal cell related cytokines
(e.g. IL-2, IL-4, IL-13, IL-17, IL-15, basic fibroblast growth factor
and epidermal growth factor) were significantly elevated in these
patients within 3 months after symptom onset, as compared with
early arthritis patients who did not develop RA. In addition, this
profile was no longer present in established RA. In contrast,
patients with non-rheumatoid persistent synovitis exhibited
elevated levels of interferon-γ at initiation. Early synovitis
destined to develop into RA is thus characterized by a distinct
and transient synovial fluid cytokine profile. The cytokines
present in the early rheumatoid lesion suggest that this
response is likely to influence the microenvironment required for
persistent RA.
Introduction
The synovium is the primary site of pathology in rheumatoid
arthritis (RA). The rheumatoid synovium contains large num-
bers of CD4+ T cells. Patients with severe disease frequently
express DR4 molecules that share an epitope in the third
hypervariable region of the β-chain [1], suggesting a patho-
genic role for T cells. However, the presence of only low levels
of T cell related cytokines in the synovium and synovial fluid of
established RA patients [2,3] led many to question the role of
T cells in persistent disease. Nevertheless, this synovial
cytokine profile is consistent with the highly differentiated
CD45RObrightRBdull phenotype of synovial T cells [4]. A widely
accepted model has emerged in which the persistence of
inflammation in established RA is driven by interactions
between T cells, macrophages and fibroblasts in an abnormal
microenvironment [5,6]. The synovial T cell population isR784
ARA = American Rheumatism Association; bFGF = basic fibroblast growth factor; CCP = cyclic citrullinated peptide; CRP = C-reactive protein; DC 
= dendritic cell; EGF = epidermal growth factor; GM-CSF = granulocyte–macrophage colony-stimulating factor; IFN = interferon; IL = interleukin; 
MCP = monocyte chemoattractant protein; MIP = macrophage inflammatory protein; PsA = psoriatic arthritis; RA = rheumatoid arthritis; RANTES = 
regulated on activation, normal T expressed and secreted; ReA = reactive arthritis; RF = rheumatoid factor; Th = T-helper (cell); TNF = tumour necro-
sis factor.
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R785maintained through active inhibition of apoptosis, mediated at
least in part by fibroblast and macrophage derived type 1 IFNs,
and active retention facilitated by fibroblast derived transform-
ing growth factor-β [7-9]. Contact dependent interactions
between T cells and macrophages stimulate the production of
proinflammatory cytokines, including tumour necrosis factor
(TNF)-α, in an antigen independent manner [10-12].
This model of persistence in established disease requires the
presence of hyperplastic synovial tissue, which is unlikely to be
present at the onset of RA. Consequently, the processes man-
ifest at initiation that lead to persistence are likely to be dis-
tinct. Difficulties in accessing patients with very early disease
and in sampling those joints involved at clinical onset have
proved to be obstacles to addressing these issues. The role of
T cells and antigen in the initiation of RA, the mechanisms that
drive early fibroblast expansion, and the interplay between T
cells and the stromal environment therefore remain obscure.
In order to study mechanisms of very early synovitis potentially
leading to RA, we established a rapid access clinic with a wide
recruitment base in which patients with synovitis were seen
within the first few weeks after symptom onset. Using a multi-
plex bead based system, allowing simultaneous analysis of
over 20 soluble molecules in very small sample volumes [13],
we measured a panel of cytokines and chemokines in the syn-
ovial fluid of patients with early inflammatory arthritis. Patients
whose disease subsequently fulfilled American Rheumatism
Association (ARA) criteria for RA had a cytokine profile char-
acterized by a range of T cell, stromal cell and macrophage
related cytokines that was not present in long-standing RA.
This profile was not seen in patients with other early arthritides.
A model was built incorporating these cytokines that distin-
guished patients who progressed to RA from other early arthri-
tis patients with a high degree of accuracy. These data
suggest that the pathological mechanisms operating at the
onset of clinically apparent RA are distinct from those in other
early inflammatory arthritides, and that these mechanisms are
transient. In addition, the present study supports the concept
that T cells play a role in disease initiation that is different from
their role in maintaining persistent inflammation.
Materials and methods
Patients
Patients were recruited through the rapid access clinic for
early inflammatory arthritis at City Hospital, Birmingham, UK.
Permission was obtained from the local ethics committee and
all patients gave written informed consent. All patients had one
or more swollen joints and symptoms (inflammatory joint pain
and/or early morning stiffness and/or joint related soft tissue
swelling) of duration 3 months or less. Patients with evidence
of previous inflammatory joint disease were excluded. Joints
were aspirated under either palpation or ultrasound guidance.
Where the synovial fluid volume in the inflamed joint was very
small (commonly at proximal interphalyngeal, metacarpopha-
lyngeal and wrist joints) direct aspiration was not possible.
Although the cellular content of these joints could be sampled
using ultrasound guided lavage [14], lavage samples were
excluded from this study because the potentially variable dilu-
tion made comparisons of the absolute levels of chemokines
and cytokines unreliable. Synovial fluid was directly aspirated
from the joints of 36 patients with non-crystal-related very early
inflammatory arthritis. In addition, for comparison, synovial fluid
was obtained from patients in three well defined diagnostic
groups: early inflammatory arthritis of crystal origin that
resolved (gout [n = 12] and pseudogout [n = 2]), established
RA (n = 9) and osteoarthritis (n = 4). Synovial fluid was col-
lected into nonheparinized tubes and spun at 1000 g for 10
min within 30 min of sample collection. The acellular portion of
synovial fluid was stored at -70°C before subsequent analysis.
The 36 patients with early inflammatory arthritis were followed
for 18 months and then assigned to their final diagnostic
groups. Patients were classified as having RA according to the
1987 ARA criteria [15], allowing criteria to be satisfied cumu-
latively. Although the 1987 ARA criteria have no exclusions,
we excluded from the RA category patients with alternative
rheumatological diagnoses explaining their inflammatory arthri-
tis. Thus, one patient, with polymyositis related arthritis, who
fulfilled criteria for RA was excluded from the RA group and
included in the non-rheumatoid persistent group. In addition,
one patient, who fulfilled criteria for RA at presentation (but
was seronegative for rheumatoid factor [RF] and anti-cyclic
citrullinated peptide [CCP] antibody), had transient disease,
remained symptom free and off all mediation at follow up, and
was included in the resolving group. Patients were diagnosed
with reactive arthritis (ReA), psoriatic arthritis (PsA) and a
number of miscellaneous conditions according to established
criteria. Of the 36 patients with non-crystal-related early
inflammatory arthritis, 14 had a resolving disease (sexually
acquired ReA [n = 4] and unclassified arthritis [n = 10]) and
22 developed persistent inflammatory arthritis (RA [n = 8],
unclassified arthritis [n = 9], PsA [n = 2] and arthritis related
to ulcerative colitis [n = 1], polymyositis [n = 1] and Behçet's
disease [n = 1]). Three of these RA patients presented with
inflammatory arthritis of just the knee or ankle joint(s) though
polyarticular synovitis, including involvement of the small joints
of the hands, developed subsequently.
Anti-CCP antibody and rheumatoid factor assay
IgG anti-CCP antibody was detected using the DIASTAT™
anti-CCP assay (Axis-Shield Diagnostics Ltd., Dundee, UK)
and seropositivity was defined as a titre of ≥5 IU/ml. RF was
measured using an ELISA (AUTOSTAT™II Total RF; Hycor
Biomedical Ltd., Penicuik, UK).
Cytokine and chemokine assay
Twenty-three cytokines and chemokines were measured
simultaneously in synovial fluid samples using a multiplex
detection kit (Biosource International, Camarillo, CA, USA): IL-
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R7861β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17,
macrophage inflammatory protein (MIP)-1α, MIP-1β, mono-
cyte chemoattractant protein (MCP)-1, RANTES (regulated on
activation, normal T expressed and secreted), eotaxin, TNF-α,
IFN-γ, granulocyte–macrophage colony-stimulating factor
(GM-CSF), granulocyte colony-stimulating factor, epidermal
growth factor (EGF), basic fibroblast growth factor (bFGF)
and vascular endothelial growth factor. A volume of 50 µl syn-
ovial fluid or of the cytokine/chemokine standards was prein-
cubated with 50 µl blocking buffer (40% normal mouse serum
[Sigma, Poole, UK], 20% goat serum [DakoCytomation Ltd,
Ely, UK] and 20% rabbit serum [DakoCytomation Ltd]; see
below) for 30 min. A volume of 50 µl diluted sample, or block-
ing buffer alone, was incubated with 25 µl of multiplex micro-
spheres for 2 hours. Microspheres were washed with
phosphate-buffered saline/0.05% Tween 20 and incubated
with 25 µl of biotinylated detection antibody, diluted in 25 µl
blocking buffer and 50 µl assay buffer (1% bovine serum albu-
min [Sigma] in phosphate-buffered saline/0.05% Tween 20),
for 1 hour. Microspheres were then washed, incubated with
streptavidin–PE at room temperature for 30 min and washed
again. Subsequently, the microspheres were resuspended in
100 µl assay buffer and analyzed (Luminex100 LabMAP™ sys-
tem; Luminex Corporation, Austin, TX, USA). Cytokine and
chemokine concentrations were calculated by reference to the
standard curve.
False-positive results, caused by cross-linking of capture and
detection antibodies by RF, are a common problem with any
immunoassay of rheumatoid samples. We tested several strat-
egies to eliminate this effect, including the absorption of RF,
and found the optimal approach in this system to be blocking
with a combination of 20% normal mouse serum, 10% rabbit
serum and 10% goat serum. The validity of the results were
assessed in two ways. First, a negative control microsphere
was produced by conjugating a microsphere, with a different
intrinsic fluorescence to any of those in the assay, to total
mouse immunoglobulin (the capture antibodies on the micro-
spheres were all mouse monoclonal antibodies). These micro-
spheres were tested in parallel with those conjugated to
specific antibodies. Second, an additional aliquot of each syn-
ovial fluid sample was tested with an entirely different detec-
tion kit obtained from an alternative source (Upstate
Biotechnology, Milton Keynes, UK). This assay uses different
antibody combinations to detect 14 of the cytokines and
chemokines measured by the primary assay (IL-1β, IL-2, IL-4,
IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, MCP-1, RANTES, eotaxin,
TNF-α and IFN-γ).
Analysis
In order to identify cytokines that distinguish patients with early
RA from other patients with early synovitis and from patients
with established RA, we performed univariate and multivariate
analyses. The Wilcoxon rank sum test was used for univariate
analysis. The false discovery rate correction was used to cor-
rect for the multiple comparisons made [16]. Results are
reported as Q values, which represent the likelihood of obtain-
ing a given P value by chance given the multiple tests per-
formed. We used a 1% false discovery rate (Q < 0.01) as our
threshold for statistical significance.
Univariate statistical tests can be used to identify cytokines
that are differentially expressed between two or more groups
of patients. However, such analyses do not address the rela-
tive significance of different combinations of cytokines
required to discriminate between different conditions. These
discriminatory profiles are likely to provide insights to the bio-
logical processes underlying the different disease states. To
identify groups of cytokines that allow the distinction of poten-
tial outcomes in patients with early arthritis, we used a classi-
fication algorithm termed Random Forest [17,18]. This
method is based on the principal of decision trees and incor-
porates efficient methods to establish the importance of each
cytokine in the classification and to perform an unbiased esti-
mate of classification error. Random Forest does not use
cross-validation or a separate training set to obtain an unbi-
ased estimate of classification error. Instead, a collection of
decision trees is constructed using a different randomly cho-
sen (bootstrap) sample of two-thirds of the data for each tree.
Each branching point, or node, is produced by using the best
of a subset of predictors randomly chosen at that node. One-
third of the cases are left out of each bootstrap sample and not
used in the construction of any given decision tree. Each of
these cases left out in the construction of a particular tree is
then put back into that tree to test the validity of the classifica-
tion obtained from the bootstrap sample. In this way, a test set
classification is obtained for each case, in about one-third of
the trees. The classification error is defined as the proportion
of patients who are misclassified. This strategy has previously
been shown to perform well compared with other classifiers,
including discriminant analysis, support vector machines and
neural networks; it is also robust against overfitting [17].
The Random Forest algorithm also estimates the relative
importance of each variable in contributing to the classification
process. In this study we used Random Forest to rank the con-
tribution of each cytokine to discrimination between outcomes
of patients with early synovitis, as a possible index of their bio-
logical contribution to this discrimination. This analysis does
not emphasize cytokines that are of general importance to
inflammation.
The models developed using Random Forest can be visualized
graphically by using multidimensional scaling to plot the rela-
tive similarity between patients in the trees [19]. This allows
the magnitude of the difference between groups, and the utility
of the data set in distinguishing different outcomes, to be
assessed.
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Patient characteristics
Baseline characteristics of patients with early inflammatory
arthritis of non-crystal origin are shown in Table 1. Patients
who developed RA were significantly older than patients in
other groups. There were no significant differences in symp-
tom duration or C-reactive protein (CRP) level at initial presen-
tation between the groups. Of the nine patients with
established RA, four were female and the median age was 62
years (interquartile range 43–74 years). There were no signif-
icant sex or age differences between the established RA and
early RA patients.
Cytokine and chemokine levels
The levels of synovial cytokines in patients with early and
established synovitis are shown in Figs 1 and 2, and the sta-
tistical significance of differences between cytokine levels in
patient groups is shown in Table 2. Patients with early synovi-
tis destined to develop RA exhibited a cytokine profile in syno-
vial fluid that was distinct from that of patients with other early
inflammatory arthritides (early synovitis that developed into
non-rheumatoid persistent disease plus non-crystal-related
resolving arthritis plus crystal-related resolving arthritis). Early
RA synovial fluid was characterized by significantly elevated
levels of T cell related cytokines (IL-2, IL-4, IL-13 and IL-17)
and stromal cell and macrophage related cytokines (EGF,
bFGF, IL-1 and IL-15) when compared with synovial fluid from
patients with other early synovitis (Figs 1 and 2, and Table 2).
Although levels of the Th2-type cytokines IL-4 and IL-13 were
elevated in patients with early RA, IFN-γ was never detected in
these patients (Fig. 1). In contrast, IFN-γ was detected in five
patients with early non-rheumatoid persistent disease (one
PsA, one ulcerative colitis related arthritis and three unclassi-
fied) and in three patients with early self-limiting disease (two
ReA and one unclassified; Fig. 1). In addition, the synovial
cytokine profile of patients with early synovitis destined to
develop RA was significantly different from that of patients
with established RA. Patients with early RA had significantly
elevated synovial levels of IL-2, IL-4, IL-13, IL-17, EGF and
bFGF when compared with patients with established RA (Figs
1 and 2, and Table 2).
We assessed the relative importance of the cytokines meas-
ured in distinguishing patients with early disease destined to
develop RA from patients with all other early arthritis together
(early disease that progressed to non-rheumatoid persistent
disease plus non-crystal-related resolving arthritis plus crystal-
related resolving arthritis) and patients with established RA.
The relative importance of each cytokine in the accuracy of
classification in these models is shown in Fig. 3a,c. IL-13,
together with IL-2, IL-4, IL-15, bFGF and EGF, were the most
important cytokines in distinguishing early RA patients from
other patients with early synovitis, with high levels of these
cytokines predicting the development of RA. Similarly, IL-13,
together with IL-2, IL-4, IL-17, bFGF and EGF, were the most
important cytokines in distinguishing early RA patients from
patients with established RA. Using this approach two of the
eight early RA patients were misclassified in both models. One
of these was an 82-year-old man who presented with a 6-week
history of synovitis (RF negative, anti-CCP antibody negative,
CRP 51 mg/l); the other was a 70-year-old woman who pre-
sented with a 10-week history of synovitis (RF positive, anti-
Table 1
Baseline characteristics of patients with early inflammatory arthritis of non-crystal origin
RA Non-RA persistent Resolving P
Number 8 14 14
Female (n) 4 6 6 NSa
Age (years)b,c 65.5 (55–73) 29.5 (23.5–61) 28.5 (21–45) 0.006d
RA versus non-RA persistent <0.05e
RA versus resolving <0.01e
Symptom duration (weeks)b,c 9 (6–9.5) 7.5 (2.5–11.5) 4 (2–8) NSd
CRP (mg/l)b,c 31 (27.5–52.5) 67 (29–172.5) 24 (3.5–45) NSd
RF ≥30 IU/ml (n) 7 0 2 <0.0001a
Anti-CCP antibodies ≥5 IU/ml (n) 7 0 1 <0.0001a
RF ≥30 IU/ml + Anti-CCP antibodies 
≥5 IU/ml (n)
7 0 0 <0.0001a
Initial NSAID use (n) 7 6 8 NSa
Initial DMARD use (n) 0 0 0 NSa
Initial prednisolone use (n) 0 3 0 NSa
Joint aspirated (knee/ankle [n]) 5/3 13/1 11/3 NSa
aχ2 test. bMedian. cInterquartile range. dKruskall–Wallis test. eWhere the medians were significantly different at the 5% level, Dunn's post-test was 
used to compare individual groups. CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; NS, 
not significant; NSAID, nonsteroidal antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor.
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between the different patients in the two models and the ability
of the synovial cytokines to distinguish between different
patient outcomes are shown in Fig. 3b,d.
The cytokine profile that was seen in patients with early RA
was transient. It was not seen in established RA (Figs 1 and 2)
or after the first few months of symptoms in patients with early
disease that went on to persist (Fig. 4). The transient nature of
the elevations in IL-2 and IL-4 in early RA synovial fluid (Fig. 4)
was also apparent for IL-13, IL-15, EGF and bFGF.
The validity of the results obtained using the multiplex assay
was confirmed in two ways. First, no significant irrelevant
staining was observed with any of the synovial fluid samples
using the negative control microspheres. The median fluores-
cence intensity of the negative control microspheres when
incubated with the synovial fluid samples was 14 (standard
deviation 2.6) and when incubated with assay buffer alone
was 16.3 (standard deviation 0.5). Second, the correlations
between the results obtained using the two different antibody
detection systems were all highly statistically significant and
were as follows (expressed as Spearman's rank correlation
[rs]): IL-1β, rs = 0.65 (P < 0.0001); IL-2, rs = 0.77 (P <
Figure 1
Synovial fluid cytokines in early and established arthritist li  rt riti . Shown are synovial fluid concentrations (pg/ml) of IL-2, IL-4, IL-13, IL-15, epidermal growth 
factor (EGF), basic fibroblast growth factor (bFGF), eotaxin and IFN-γ. Patient groups: 1, early synovitis that develops into rheumatoid arthritis (RA); 
2, early synovitis that develops into non-rheumatoid persistent synovitis; 3, early non-crystal-related resolving synovitis; 4, crystal-related resolving 
synovitis; 5, established RA; and 6, osteoarthritis.
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0.0001); IL-6, rs = 0.95 (P < 0.0001); IL-8, rs = 0.8 (P <
0.0001); IL-10, rs = 0.56 (P < 0.0001); IL-12, rs = 0.27 (P =
0.006); MCP-1, rs = 0.72 (P < 0.0001); RANTES, rs = 0.84 (P
< 0.0001); TNF-α, rs = 0.47 (P < 0.0001); and IFN-γ, rs = 0.54
(P < 0.0001). Levels of eotaxin and IL-13 were below the
detection limit of the second assay.
There was no significant correlation between the RF titre and
the levels of any of the cytokines or chemokines measured in
patients with early RA. Correlations between CRP and levels
of chemokines and cytokines in early inflammatory arthritis syn-
ovial fluid were statistically significant only for IL-6 (rs = 0.49 [P
= 0.003]), TNF-α (rs = 0.37 [P = 0.03]), IFN-γ (rs = 0.52 [P =
0.001]) and vascular endothelial growth factor (rs = 0.47 [P =
0.004]). These correlations were independent of outcome. An
independent analysis of the eight patients with early RA
revealed no correlation between CRP and the level of any
chemokine or cytokine.
Discussion
The synovium of patients with established RA is expanded and
contains large numbers of fibroblasts, macrophages and
highly differentiated T cells [20]. Although the mechanisms
responsible for persistence of this infiltrate in established dis-
ease have been well characterized (for review [5,21,22]),
Figure 2
Synovial fluid cytokines in early and established arthritis. Shown are synovial fluid concentrations (pg/ml) of IL-1β, macrophage inflammatory protein 
(MIP)-1β, granulocyte–macrophage colony-stimulating factor (GM-CSF), IL-12, MIP-1α, monocyte chemoattractant protein (MCP)-1, IL-17, IL-10, 
granulocyte colony-stimulating factor (G-CSF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF)-α, RANTES (regulated on 
activation, normal T expressed and secreted), IL-8, IL-6 and IL-5. Patient groups: 1, early synovitis that develops into rheumatoid arthritis (RA); 2, 
early synovitis that develops into non-rheumatoid persistent synovitis; 3, early non-crystal-related resolving synovitis; 4, crystal-related resolving syn-
ovitis; 5, established RA; and 6, osteoarthritis.
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groups have studied RA at a relatively early stage from patho-
logical, radiological and therapeutic perspectives. The maxi-
mum duration of symptoms accepted for recruitment to such
studies has been highly variable, usually ranging from less than
1 year to less than 3 years [23-26]. However, the observation
that spontaneous remission is unusual if inflammatory arthritis
has persisted for longer than 6 months [27] suggests that
pathological mechanisms driving the switch to persistence are
already established by this time. In contrast, the concept that
RA patients with a much shorter disease duration may be
within a therapeutically distinct window is supported by a
study in which remission was more commonly induced in
patients with disease of ≤4 months duration compared with
longer duration disease [28]. However, the confounding effect
of differential rates of spontaneous remission has been difficult
to exclude. Whether this very early phase of disease is patho-
logically distinct remains to be determined.
Within the first 12 weeks after symptom onset, we found that
the synovial fluid of patients who eventually developed RA was
characterized by a wide range of cytokines and chemokines.
Some, such as IL-6, were present in all inflammatory
arthritides, suggesting their importance in synovitis per se
rather than a specific role in rheumatoid synovitis. In contrast,
early RA patients had a distinct and consistent synovial
cytokine profile characterized by T cell, macrophage and stro-
mal cell related cytokines (in particular IL-2, IL-4, IL-13, IL-17,
IL-1, IL-15, bFGF and EGF), which was not seen in other early
arthritides. This profile was transient, and was no longer
present in any patients with established RA. Seven of the eight
patients whose disease developed into RA already expressed
RF and anti-CCP antibody at this early stage, within weeks of
symptom onset. Several groups have shown that these anti-
bodies can be found in patients who subsequently develop
RA, long before symptoms are apparent [29-31], implying a
preclinical pathology. Our data are entirely compatible with the
possibility of a preclinical phase of disease in patients with RA.
We are clearly unable to address the issue of how the synovial
cytokine profile within the first few months of symptoms com-
pares with that which may be present during a preclinical
phase of disease. However, our data do suggest that the path-
ological processes operating in the rheumatoid joint within the
first few weeks after symptom onset differ from those proc-
esses operating in other early synovial lesions, and that these
processes are transient.
Table 2
Comparisons between synovial fluid cytokineconcentrations in patients with early synovitis that develops into rheumatoid arthritis 
and other patient groups
Cytokine Early RA versus all other early synovitis Early RA versus established RA
P Q P Q
IL-13 <0.00001 0.00002 0.00008 0.0004
EGF <0.00001 0.00002 0.002 0.007
bFGF <0.00001 0.00002 0.002 0.007
IL-4 <0.00001 0.00002 0.004 0.0097
IL-2 <0.00001 0.00002 0.004 0.0097
Eotaxin 0.00003 0.0002 NS NS
IL-1 0.00003 0.0002 NS NS
IL-17 0.00005 0.0003 0.002 0.007
IL-15 0.0001 0.0005 NS NS
MIP-1β 0.0005 0.002 NS NS
MIP-1α 0.0006 0.002 NS NS
IL-12 0.002 0.006 NS NS
GM-CSF 0.002 0.006 NS NS
G-CSF 0.004 0.0097 NS NS
Comparator groups were, first, patients with all other early synovitis (synovitis that develops into non-rheumatoid persistent synovitis plus non-
crystal-related resolving synovitis plus crystal-related resolving synovitis) and, second, patients with established rheumatoid arthritis (RA). Groups 
were compared using the Wilcoxon rank sum test. The significance of the difference between groups is shown (P). The false discovery rate 
correction was used to correct for the multiple comparisons made. Results are reported as Q values, which represent the likelihood of obtaining a 
given P value by chance, given the multiple tests performed. For cytokines not shown there were no significant differences between groups (a 1% 
false discovery rate [Q < 0.01] was used as the threshold for statistical significance). bFGF, basic fibroblast growth factor; EGF, epidermal 
growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte–macrophage colony-stimulating factor; IL, interleukin; MIP, 
macrophage inflammatory protein; NS, not significant.
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duration of <1 year) and established RA, immunohistological
analysis of the synovium, including an assessment of TNF-α,
IL-1β and IL-6 expression, did not reveal any differences
between early (mean disease duration 6 months) and long-
standing disease [23]. Expression of IFN-γ, IL-10 and IL-12
mRNA in synovial fluid mononuclear cells were also similar
between such early patients and those with established RA
[32]. However, very few groups have studied the pathology of
RA within the first few weeks of symptom onset. Indeed,
Figure 3
Importance of individual cytokines in classifying patient groups. Plots represent models discriminating patients with early inflammatory arthritis who 
develop rheumatoid arthritis (RA) from (a,b) all other early inflammatory arthritis patients (early disease that progresses to non-rheumatoid persistent 
disease plus early non-crystal-related resolving arthritis plus crystal-related resolving arthritis) and from (c,d) established RA. Panels a and c show 
the relative importance of the cytokines in the overall classification. The vertical axes represent individual cytokines arranged according to impor-
tance. The horizontal axes represent the average decrease in classification accuracy seen when the values for each cytokine are permuted. Important 
cytokines are associated with a greater decrease in classification accuracy. The plots shown in panels b and d are metric multidimensional scaling 
(MDS) representations of the proximity matrices of the Random Forest models demonstrating the relationship between individual patients in the two 
models. The two axes represent the first and second MDS axes. Closed circles represent patients with early inflammatory arthritis who develop RA 
in both panels; open circles represent patients with (panel b) all other early inflammatory arthritis and (panel d) established RA.
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weeks cannot fulfil 1987 ARA classification criteria for RA
[15], any study of early disease that limits itself to patients ful-
filling these criteria will exclude those with very early synovitis.
We studied patients with inflammatory arthritis of duration 3
months or less, recruited through a rapid access clinic. The
assignment of patients to specific diagnostic categories was
done subsequently at clinical follow up. In one of the few other
studies of the pathology of very early inflammatory arthritis,
synovial histology was assessed in 24 patients with disease of
duration under 2 months [33]. Nine patients had transient syn-
ovitis and six developed RA. Interestingly, there were no clear
histological differences between these patients. In contrast,
our results suggest that pathological mechanisms operating at
the onset of clinically apparent RA are different from those in
patients with other early arthritides. The results also show a
surprising degree of uniformity between RA patients in this
early phase of disease.
The concept that T cells play an important role in the initiation
of RA, with antigen specific T cells mediating autoimmunity, is
not new (for review [34]). However, robust evidence to
support such a role for T cells has been lacking. The observa-
tion in this report of consistently elevated T cell derived
cytokines strongly suggests T cell activity in early RA. The
clear difference between the levels of specific T cell related
cytokines in early RA and other early inflammatory arthritides,
as well as established RA, suggests a pathological process
that is specific to early RA and that is transient. The Th2
cytokine pattern, with a marked absence of IFN-γ and predom-
inance of IL-4 and IL-13, in the earliest clinically apparent RA
lesions was unexpected. Current paradigms suggest the
cytokine balance in established RA to be skewed in favour of
a Th1-type response [34]. In established RA, synovial T cells
produce IFN-γ after in vitro stimulation [35], and mRNA for
IFN-γ but not IL-4 is found in synovial fluid mononuclear cells
[32]. However, recent evidence from mouse models suggests
that IFN-γ plays a significant role in the resolution of synovial
inflammation [36]. In murine models of Leishmania infection, a
Th2 polarized response leads to persistent disease, whereas
a Th1 polarized delayed-type hypersensitivity response leads
to resolution [37]. This is similar to the effects seen in human
leprosy [38]. The discrepancy between IFN-γ levels in early RA
and other early arthritides may consequently be of relevance to
the pathology of the transition to persistent inflammation. In
addition, T cells cloned from early rheumatoid synovium have
been shown to produce significantly more IL-4 than those from
long-standing disease [39]. When T cells were re-cloned from
an early patient at a subsequent time point, IL-4 production
was significantly diminished [39]. These findings concur with
the data reported here, suggesting a transient Th2 phenotype
in early RA synovial fluid.
The role of the Th2-type cytokines in early RA is unclear. IL-4
has divergent proinflammatory and anti-inflammatory effects in
Figure 4
Longitudinal synovial fluid cytokine concentrations (pg/ml) in patients with early inflammatory arthri is
with early inflammatory arthritis. Results are shown for patients with 
early inflammatory arthritis who develop rheumatoid arthritis (closed cir-
cles) and non-rheumatoid persistent inflammatory arthritis (open cir-
cles) for (a) IL-2, (b) IL-4 and (c) IFN-γ.
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proliferation and CD154 (CD40 ligand) expression in lung
fibroblasts [42,43] and is important in inducing fibrosis in Th2
mediated diseases such as schistosomiasis [44]. In addition,
both IL-4 and IL-13 protect synoviocytes against nitric oxide
induced apoptosis [45]. The pro-survival and proliferative
effects of these cytokines may be important in the develop-
ment of the expanded fibroblast network, which occurs during
early disease and which characterizes established RA [46].
The presence of significant levels of the autocrine synovial
fibroblast growth factors bFGF and EGF [47] clearly supports
this process. The absence of these growth factors in the syn-
ovial compartment of patients with self-limiting disease is not
surprising, because one would not expect an expanded fibrob-
last layer (which would mediate the switch to persistence) in
such patients. Interestingly, however, these growth factors
were absent in non-RA persistent inflammatory arthritis, sug-
gesting a difference between the mechanism of synovial
hyperplasia in early RA and other persistent inflammatory
arthritides.
Th2-type cytokines have additional effects on synovial fibrob-
lasts that may be relevant in early RA. Cultured synovial fibrob-
lasts have a global gene expression profile that is quite
different from that of lymph node and tonsil fibroblasts [48].
However, the addition of IL-4 to synovial fibroblasts dramati-
cally modulates their gene expression profile, which converges
with that of fibroblasts from secondary lymphoid tissue [48].
Germinal centre-like structures are seen in the synovium of
many RA patients [49]. The synovial environment in early RA
may modulate fibroblast function, leading to the production of
factors facilitating lymphoid aggregate formation and allowing
local RF production.
The distinct T cell related cytokine profile observed in patients
with early RA supports the concept that T cells play an impor-
tant role at the onset of clinically apparent disease. Tissue den-
dritic cells (DCs) are specialized for high antigen capture and
migration into draining lymph nodes, where they are essential
for activating naïve T cells. The role played by DCs in the onset
of inflammatory arthritis has been explored in a murine model,
in which collagen pulsed mature DCs induced inflammatory
arthritis when transferred into DBA/1 mice [50]. Characteriza-
tion of the T cell response in draining lymph nodes revealed
significant proliferation of collagen specific T cells and IL-2
production, suggesting that priming of autoreactive T cells by
DCs may play a role in disease initiation. Blood monocytes
may differentiate into DCs in the presence of GM-CSF, IL-4
and TNF-α [51] and early myeloid DC progenitors in RA syno-
vial fluid differentiate in response to IL-4 or IL-13 in combina-
tion with GM-CSF and stem cell factor [52]. The synovial
cytokine environment in early RA may thus stimulate mature
DC production and consequent T cell activation.
The recruitment of leucocytes into the synovial compartment is
regulated, in part, by chemokines. Although levels of the chem-
okines measured (e.g. MIP-1α, MIP-1β, MCP-1 and RANTES)
were elevated in the synovial fluid of many patients with early
RA, they were of limited value in distinguishing early RA from
other early arthritides or from established RA. The chemokine
stromal cell-derived factor 1 (SDF-1; CXC chemokine ligand
12 [CXCL12]) has been implicated in the recruitment and
retention of T cells and monocytes into the rheumatoid syn-
ovium [9,53]. Unfortunately, no combination of monoclonal
antibodies could be found that produced reliable estimates of
SDF-1 using the multiplex detection strategy, so we were una-
ble to measure this chemokine.
Several roles can be proposed for the other cytokines found in
early RA. IL-17 has pleiotropic effects on leucocytes and stro-
mal cells (for review [54]). For example, it induces IL-6 and IL-
8 production by fibroblasts [55] and stimulates macrophage
IL-1 and TNF-α production [56]. IL-15 stimulated T cells
induce macrophage-mediated TNF-α production [11]. In addi-
tion, all common γ-chain cytokines, including IL-2, IL-4 and IL-
15, are potent T cell survival factors [57], which may support
the persistence of the early rheumatoid lesion.
Conclusion
The data presented herein suggest that the pathology of RA
within the first few months after symptom onset is distinct from
that of other early inflammatory arthritides and of established
RA. The nature of the cytokines present in the synovial fluid of
patients with early RA suggests that this response is likely to
influence the microenvironment required for persistent
disease.
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